BOSTON, Jan. 23, 2019 /PRNewswire/ -- Molecular Engineer Chris Bahl has been selected as a TED Fellow, joining a class of 20 change-makers from around the world to deliver a talk on the TED stage this April in Vancouver. Bahl was selected for his pioneering work on the de novo design of novel mini-proteins and constrained peptides, an innovative approach for creating therapeutics with the potential to tackle long-standing challenges in medicine and human health.
"The TED fellowship is an amazing opportunity to share our work with a wide audience. Scientific communication is vitally important, and the general public deserves to know about our exciting discoveries and innovations. I am pleased to join the TED community and very thankful to be included in the 2019 class of TED Fellows," said Bahl.
Bahl is Head of Protein Design at Institute for Protein Innovation (IPI). His team is leveraging the latest advances in computational design to accelerate the creation of new protein-based drugs to treat a wide range of diseases.
"We are thrilled to announce the newest class of TED Fellows, who give voice to some of the most exciting ideas we've seen in the program's 10-year history," said TED Fellows director Shoham Arad. "This year's class includes a police captain designing systems to support women in policing, a space environmentalist building technology to monitor space debris, and an artist exploring the ethical implications of emerging technology. The Fellows program is committed to using its resources and platform to help scale Fellows' ideas and impact, and we are so excited to have these Fellows become an integral part of our global community."
About the TED Fellows program
Founded in 2009, the TED Fellows program has 473 Fellows from 96 countries, whose talks have been viewed more than 250 million times overall. In its ten-year history, the TED Fellows program has created a powerful, far-reaching network made up of scientists, doctors, activists, artists, entrepreneurs, inventors, journalists, and innovators from around the world who display both outstanding achievement and exemplary character, to raise international awareness of their work and maximize their impact.
IPI is a non-profit research organization whose mission is to foster innovation in protein research and bridge the missing link between genomics and therapeutics. IPI has built a high-throughput antibody discovery platform for developing open-source antibodies targeting the entire human extracellular proteome. This resource will produce critical tools, lead therapeutics, and technologies that empower academic and industry scientists, catalyze entrepreneurship, and accelerate drug discovery.
SOURCE Institute for Protein Innovation